PSYKONOS
Psykonos is a cutting-edge biotech company focused on revolutionizing the diagnosis of bipolar disorder. They have identified proprietary blood biomarkers and utilize advanced analytical methods and artificial intelligence to accurately diagnose bipolar disorder and differentiate it from other conditions like major depressive disorder. The company aims to significantly reduce the current average diagnostic delay of 8 years, enabling earlier and more appropriate treatment for patients. Their breakthrough has the potential to transform the diagnosis and treatment landscape for bipolar disorder.
PSYKONOS
Psykonos is a cutting-edge biotech company focused on revolutionizing the diagnosis of bipolar disorder. They have identified proprietary blood biomarkers and utilize advanced analytical methods and artificial intelligence to accurately diagnose bipolar disorder and differentiate it from other conditions like major depressive disorder. The company aims to significantly reduce the current average diagnostic delay of 8 years, enabling earlier and more appropriate treatment for patients. Their breakthrough has the potential to transform the diagnosis and treatment landscape for bipolar disorder.